Navigation Links
Investigational Compound Offers Novel Anti-IGF Approach To Inhibit Growth of Cancer Cells
Date:1/20/2011

GAITHERSBURG, Md., Jan. 20, 2011 /PRNewswire/ -- MedImmune's Oncology group announced today preclinical results showing that MEDI-573, a targeted monoclonal antibody, broadly suppresses pathways that have been shown to play a critical role in the development and progression of many solid tumors. The study, published in the February 1 issue of Cancer Research (a journal of the American Association for Cancer Research), suggests that MEDI-573 inhibits multiple biological pathways related to cancer.  

MEDI-573 is the only human monoclonal antibody (MAb) currently under clinical development that neutralizes both insulin-like growth factor (IGF)-I and IGF-II, growth hormones that regulate cell growth, survival, differentiation, and transformation (i.e., the process of acquiring cancerous characteristics). This MedImmune compound specifically inhibits IGF signaling through two important pathways: IGF-1R and IR-A (insulin receptor isoform A). Unlike the other IGF-1R-targeting MAbs in development that target only IGF-1R, MEDI-573 neutralizes both the receptors IGF-1R and IR-A as well as their hybrid receptors.  In addition, MEDI-573 spares the insulin receptor isoform B (IR-B), which interacts with insulin and is crucial for the metabolism of glucose – the body's main source of energy. Therapies that affect IR-B have been shown to raise or drop blood sugar levels, both of which can cause serious health problems. Preliminary data from MedImmune's first-time-in-human study suggest that MEDI-573 does not alter glucose homeostasis.

"MEDI-573 represents an innovative approach for the treatment of solid tumors with the potential for greater and more consistent inhibition of cancer cell growth than treatments that only target one pathway," said Jin Gao, Ph.D., Scientist II in Oncology Research at MedImmune and lead author of the study.  "The data from our pre-clinical studies are highly promising.  Ongoing studies in humans will pr
'/>"/>

SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
3. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
4. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
5. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
6. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
7. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
8. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
9. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
10. Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps
11. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Budding Biomedical ... University School participated in the Scientific ... Reserve University’s School of Medicine . ... an unparalleled professional experience in the sciences and ... Medicine faculty and students for both academic and ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed data of ... virus strains has revealed extensive conservation and sharing of ... sharing of specific Replikin gene structures has permitted the ... did for the H5N1 influenza vaccine and the Taura ... to be effective (1,2). This ...
(Date:8/26/2014)... REHOVOT, Israel , August 26, 2014 /PRNewswire/ ... specialist, Replica 3DM, supports NHS hospitals with surgery validation using ... - Performing surgery on 3D printed models ... patient recovery and provides an effective aid for both patient ... (Nasdaq: SSYS ), a global leader of 3D ...
(Date:8/26/2014)... AVENTURA. Fla. , Aug. 26, 2014 /PRNewswire/ ... trades under the symbol (NUUU) has two (2) ... Inc. Our two subsidiaries harness scientifically advanced technology ... NUUU,s Renuell Int,l, Inc. ... breakthrough anti-aging skin care products that is made ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2
... 11 Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ... Blair & Company 28th Annual Growth Stock Conference in ... Time., A live webcast of the presentation can ... . The webcast will,be archived for replay following ...
... N.J., June 11 Veridex, LLC announced,today that it ... of the assets of Immunicon Corporation (OTC Bulletin,Board: IMMC) ... date,adjustments, plus the discharge and release of certain claims ... liabilities., The assets to be acquired include intellectual ...
... recognized in premier program ... for the medical technology community, ... the company,s RealHand High Dexterity (HD) instruments were,recognized with ... an excellent job thinking ,outside of the box, to ...
Cached Biology Technology:Veridex Announces Agreement to Acquire the Assets of Immunicon Corporation 2Novare Surgical Wins Medical Design Excellence Award 2
(Date:8/26/2014)... At the stroke of a pen a New Zealand endemic ... the same as a group of ,weedy, Australian shrubs and ... study to reveal some surprises and discover astonishing cryptic diversity ... study was published in the open access journal ... ericoides , this species was one of the many discoveries ...
(Date:8/26/2014)... such as global warming and poverty the result ... fall on our failure as consumers to make ... in the Journal of Consumer Research , ... problems from governments to consumers and ultimately benefits ... politicians to encourage responsible consumption instead of implementing ...
(Date:8/26/2014)... new analysis suggests the planet can produce much more ... roots, fruits, grains and other terrestrial plant parts ... in Environmental Science and Technology , recalculates the ... it is much higher than many current estimates allow. ... whole planet, you have to make some simplifying assumptions," ...
Breaking Biology News(10 mins):And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3An inconvenient truth: Does responsible consumption benefit corporations more than society? 2Study: Earth can sustain more terrestrial plant growth than previously thought 2Study: Earth can sustain more terrestrial plant growth than previously thought 3
... in humanity,s greatest achievements but scientists have found that working ... chimpanzees. A series of trials by scientists found ... also understand the need to help a partner perform their ... were given tools to get grapes out of a box. ...
... known risk factor for back pain and disc disease. ... Annual Meeting of the American Academy of Orthopaedic Surgeons ... in 6,779 patients undergoing treatment for spinal disorders with ... each patient,s age, gender, weight, smoking history, assessment of ...
... Stingrays living in one of the world,s most famous ... the Cayman Islands have profoundly changed their ways, ... on marine wildlife, reports a new study published March ... Researchers from Nova Southeastern University,s Guy Harvey Research ...
Cached Biology News:Origins of human teamwork found in chimpanzees 2Origins of human teamwork found in chimpanzees 3Tourist-fed stingrays change their ways 2
...
Mouse polyclonal antibody raised against a partial recombinant PREB. NCBI Entrez Gene ID = 10113...
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
... Blocker Array II can be used ... against various proteins and sera that are ... carriers. The array contains spots for 19 ... Application: Determination of antibody crossreactivity and species ...
Biology Products: